CONTAIN COVID-19 was a randomized, double-blinded, phase 2 controlled trial which examined the safety and efficacy of convalescent plasma versus a placebo (saline solution) to treat patients who were hospitalized with COVID-19.

Inclusion criteria:

• Being at least 18 years of age
• Hospitalization with laboratory-confirmed COVID-19
• At least one respiratory sign or symptom: cough, chest pain, shortness of breath, fever, oxygen saturation ≤94%, abnormal CXR/CT imaging
• Hospitalization for ≤72 hours OR ≤ 7 days from the first signs of illness
• Treatment with supplemental oxygen, non-invasive ventilation or high-flow oxygen

Exclusion criteria:

• Receipt of pooled immunoglobulin in past 30 days
• Receipt of a COVID-19 vaccine
• Contraindication to transfusion or history of prior reactions to transfusion blood products
• Invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
• Volume overload secondary to congestive heart failure or renal failure
• Unlikely to survive past 72 hours from screening based on the assessment of the investigator
• Unlikely to be able to assess and follow outcome due to poor functional status

The provided dataset contains de-identified data from 941 patients who were enrolled from 21 sites across the United States. Available data include demographic details, baseline history, baseline medications, baseline laboratory values, clinical status (based on the WHO 11-point Clinical Progression Scale) at 14 and 28 days after randomization, antibody titers, and randomization assignment.